The relationships between the chemosensitivity of human gastric cancer to paclitaxel and the expressions of class III β-tubulin, MAPT, and survivin
The relationships between the chemosensitivity of human gastric cancer to paclitaxel and the expressions of class III β-tubulin, MAPT, and survivin
复制标题
DOI：
10.1007/s12032-014-0950-3
复制
发表时间：
2014-05-01
期刊：
影响因子：
3.4
通讯作者：
Wu, Changping
中科院分区：
文献类型：
--
作者：
He, Wenting;Zhang, Dachuan;Wu, Changping
缺乏有效的生物标志物是目前化疗中预测药物反应和敏感性的挑战之一。本研究旨在探讨III型β-微管蛋白、微管相关蛋白tau、Survivin的表达与胃癌紫杉醇治疗敏感性的关系。用逆转录聚合酶链式反应和Western印迹法检测54例胃癌组织中III型β-微管蛋白、MAPT和Survivin的mRNA和蛋白表达。以三磷酸腺苷为基础的体外肿瘤药敏试验检测了胃癌存活肿瘤细胞对紫杉醇的敏感性。在54份标本中，30份对紫杉醇敏感，24份耐药。紫杉醇的总有效率为55.56%(30/54)。III型β-微管蛋白和Survivin的表达与组织学分级显著相关(P分别为0.029和0.009)。胃癌患者对紫杉醇治疗的敏感性与III型β-微管蛋白(P<；0.01)、MAPT(P<；0.05)和Survivin(P<；0.05)的表达呈负相关。III型β-微管蛋白与MAPTmRNA和蛋白表达呈显著正相关(m RNA：P=0.037；P=0.001)。我们的结果表明，III类β-微管蛋白、MAPT和Survivin的表达水平是预测胃癌对紫杉醇治疗敏感性的良好生物标志物。
Lack of effective biomarkers is one of the challenges in current chemotherapy to predict drug response and sensitivity. This study was carried out to investigate the relationships between the expressions of class III beta-tubulin, microtubule-associated protein tau (MAPT), survivin, and the sensitivity of primary gastric cancer (GC) to paclitaxel treatment. Reverse transcription PCR and Western blot were used to evaluate the mRNA and protein expressions of class III beta-tubulin, MAPT, and survivin in fifty-four GC tissues. Viable tumor cells from gastric carcinomas were tested for their sensitivity to paclitaxel using adenosine triphosphate-based tumor chemosensitivity assay in vitro. Out of 54 samples, 30 samples were sensitive to paclitaxel, while the other 24 samples were resistant. The overall efficacy of paclitaxel was 55.56 % (30/54). The mRNA expressions of class III beta-tubulin and survivin were significantly correlated with the histological grade (P = 0.029, 0.009, respectively). The sensitivity of GC patients to paclitaxel treatment was inversely correlated with the mRNA and protein expressions of class III beta-tubulin (P < 0.01), MAPT (P < 0.05), and survivin (P < 0.05). A significant positive correlation was found between class III beta-tubulin and MAPT expression at mRNA and protein levels (mRNA: P = 0.037; protein: P = 0.001). Our results indicate that the expression levels of class III beta-tubulin, MAPT, and survivin are good biomarkers for predicting the sensitivity of GC to paclitaxel treatment.